GIP and GLP-1 receptor co-agonist
VK2735 2.5 mg injection once weekly
VK2735_SC_2p5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.62 (0.18 to 12.52) | 0.42 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.96 (0.06 to 9.48) | 0.65 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.25 (0.45 to 3.44) | 0.84 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.50 (0.40 to 17.71) | 0.64 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.78 (1.15 to 13.74) | 0.24 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.61 (0.44 to 5.95) | 0.58 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 3.74 (0.16 to 78.44) | 0.31 |